Metozolv Odt

Gastroparesis, Aerophagy, Migraine + 23 more

Treatment

4 FDA approvals

20 Active Studies for Metozolv Odt

What is Metozolv Odt

Metoclopramide

The Generic name of this drug

Treatment Summary

Metoclopramide is a medication used to treat nausea, vomiting, and other symptoms of diabetic gastroparesis. It can also be used to prevent nausea or vomiting associated with chemotherapy or certain types of surgeries or tests. It is unique in that it does not increase stomach acid production. Metoclopramide comes in tablet form, liquid form, or can be given intravenously. It was first approved by the FDA in 1980.

Metoclopramide

is the brand name

Metozolv Odt Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Metoclopramide

Metoclopramide

1985

199

Approved as Treatment by the FDA

Metoclopramide, commonly known as Metoclopramide, is approved by the FDA for 4 uses including Gastroesophageal reflux disease and Gastroesophageal Reflux Disease (GERD) .

Gastroesophageal reflux disease

Gastroesophageal Reflux Disease (GERD)

Failed conventional therapy

Gastroparesis

Effectiveness

How Metozolv Odt Affects Patients

Metoclopramide helps to empty the stomach by reducing the pressure of the lower esophageal sphincter. It also helps to reduce nausea and vomiting. This drug will speed up digestion without increasing the amount of acid, bile, or enzymes that are produced. However, it should not be taken for more than 12 weeks as it can cause side effects such as tardive dyskinesia, dystonia, and akathisia.

How Metozolv Odt works in the body

Metoclopramide helps stop nausea and vomiting by blocking certain receptors in the brain. It also helps speed up digestion by boosting the release of a chemical called acetylcholine, which helps relax the muscles in your stomach and intestines. Metoclopramide also blocks dopamine receptors, which usually help relax the gastrointestinal tract.

When to interrupt dosage

The measure of Metozolv Odt is contingent upon the diagnosed affliction, including Nausea, Intubation (method) and Gastroesophageal Reflux Disease (GERD). The amount additionally fluctuates as per the procedure of administration (e.g. Spray or Tablet, orally disintegrating) detailed in the table beneath.

Condition

Dosage

Administration

Nausea

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

gastric emptying for radiologic procedures

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Therapeutic procedure

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Gastric Motility Disorder

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

prophylaxis of Hiccups

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

meteorism

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Nausea

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Failed conventional therapy

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Acute Coryza

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Nausea

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Hyperacidity

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

radiation therapy induced nausea and vomiting

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Aerophagy

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Flatulence

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Indigestion

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Gastrointestinal distress

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Hiccup

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Nausea

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Pharmacotherapy

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Intubation (procedure)

10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL

, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Warnings

Metozolv Odt Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Metoclopramide may interact with Pulse Frequency

Mechanical Intestinal Obstruction

Do Not Combine

Gastrointestinal Hemorrhage

Do Not Combine

Gastrointestinal Perforation

Do Not Combine

Paraganglioma

Do Not Combine

Tardive Dyskinesia

Do Not Combine

Pharmaceutical Preparations

Do Not Combine

Pheochromocytoma

Do Not Combine

Parkinson's Disease

Do Not Combine

Depression

Do Not Combine

Epilepsy

Do Not Combine

Gastrectomy

Do Not Combine

Dystonia

Do Not Combine

Feeling suicidal (finding)

Do Not Combine

There are 20 known major drug interactions with Metozolv Odt.

Common Metozolv Odt Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.

Aceprometazine

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Aceprometazine.

Acetophenazine

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetophenazine.

Alimemazine

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Alimemazine.

Amisulpride

Major

The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.

Metozolv Odt Toxicity & Overdose Risk

The lowest toxic dose of metoclopramide for rats is 750 mg/kg. Overdosing on metoclopramide can cause drowsiness, confusion, and movement disorders. Medications to treat Parkinson's disease, anticholinergic drugs, or antihistamines with anticholinergic properties may help reduce these symptoms. In infants, an overdose of metoclopramide can cause seizures, movement disorders, and a lethargic state. Methemoglobinemia (a condition where the blood cannot carry enough oxygen) has also been linked to overdoses in newborns, which can be treated with methylene

image of a doctor in a lab doing drug, clinical research

Metozolv Odt Novel Uses: Which Conditions Have a Clinical Trial Featuring Metozolv Odt?

Research is currently being conducted for 113 studies to evaluate the potential of Metozolv Odt in providing Migraine, Nausea and Pharmacotherapy relief.

Condition

Clinical Trials

Trial Phases

Gastroparesis

15 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Early Phase 1

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Gastric Acid

0 Actively Recruiting

Gastroesophageal Reflux Disease (GERD)

9 Actively Recruiting

Not Applicable, Phase 2

Flatulence

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Pharmacotherapy

0 Actively Recruiting

Indigestion

6 Actively Recruiting

Phase 3, Not Applicable, Phase 2

radiation therapy induced nausea and vomiting

0 Actively Recruiting

Nausea

0 Actively Recruiting

Gastrointestinal distress

9 Actively Recruiting

Phase 2, Early Phase 1, Phase 1, Phase 3, Not Applicable, Phase 4

Hiccup

0 Actively Recruiting

Failed conventional therapy

0 Actively Recruiting

meteorism

0 Actively Recruiting

Nausea

0 Actively Recruiting

Gastric Motility Disorder

0 Actively Recruiting

Aerophagy

0 Actively Recruiting

Intubation (procedure)

0 Actively Recruiting

gastric emptying for radiologic procedures

0 Actively Recruiting

prophylaxis of Hiccups

0 Actively Recruiting

Metozolv Odt Reviews: What are patients saying about Metozolv Odt?

5

Patient Review

7/28/2010

Metozolv Odt for Condition in which Stomach Acid is Pushed Into the Esophagus

I've only been on this medication for a week, but it has already shown to be effective.

5

Patient Review

3/12/2010

Metozolv Odt for Stomach Muscle Paralysis and Decreased Function from Diabetes

This treatment worked well for me with no side effects.

4.3

Patient Review

3/3/2010

Metozolv Odt for Condition in which Stomach Acid is Pushed Into the Esophagus

GERD caused me a lot of discomfort by creating gas bubbles in my chest/esophagus. This medication, taken half an hour before dinner, reduced my symptoms four out of five nights and allowed me to sleep uninterrupted.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about metozolv odt

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is metoclopramide used for?

"Metoclopramide can be used to help stop you feeling or being sick if you are undergoing radiotherapy or chemotherapy, or if you are experiencing sickness due to a migraine."

Answered by AI

Is Propulsid available in the US?

"The brand name Propulsid is not available in the U.S., but there may be generic versions available."

Answered by AI

What does ODT medication?

"An orally disintegrating tablet is a type of pill that is designed to dissolve on the tongue, rather than being swallowed whole. This type of pill is available for a limited range of over-the-counter and prescription medications."

Answered by AI

What is the side effects of metoclopramide?

"Some of the symptoms of the flu include feeling very tired, weak, and dizzy. You may also have a headache, and some people experience nausea and vomiting. Diarrhea is another symptom that some people experience when they have the flu."

Answered by AI

Clinical Trials for Metozolv Odt

Image of University of Texas Medical Branch in Galveston, United States.

Middle Meningeal Artery Stimulation for Migraine

18 - 100
All Sexes
Galveston, TX

This study is testing a new way to help with migraine headaches. Researchers want to see if it's safe and doable to stimulate a blood vessel in the head (called the middle meningeal artery) with microcatheters and microwires. This has never been done before for migraines and is an investigational treatment that is not part of standard migraine treatment. This stimulation would happen just before giving the standard lidocaine treatment, which is already routinely used for migraines. The goal is to see whether this new step could help improve headache outcomes. Two FDA-cleared medical devices will be used, the Cadwell Cascade 32 PRO and the Cadwell Guardian IONM System, to perform the stimulation and monitoring. In this study, the Cascade 32 PRO will be used in a way that is not part of its usual approved purpose (this is called "off-label" use) to gently deliver electrical pulses through a microcatheter. The Cadwell Guardian IONM System will be used in its normal, FDAapproved way for continuous monitoring during stimulation.

Recruiting
Has No Placebo

University of Texas Medical Branch

Peter Kan, MD,MPH

Image of University of Rochester Medical Center in Rochester, United States.

Medical Cannabis for Nausea and Vomiting

18+
All Sexes
Rochester, NY

Many people receiving chemotherapy experience nausea despite standard anti-nausea medications. Medical cannabis is commonly used to help manage nausea, but there is limited scientific evidence about its effectiveness when used alongside modern chemotherapy treatments. This study will evaluate whether medical cannabis can reduce nausea in adults receiving moderately or highly nausea-causing chemotherapy. Participants will be randomly assigned to start medical cannabis either immediately or after one chemotherapy cycle, allowing comparison of symptoms with and without cannabis use. All participants will continue their usual anti-nausea medications. The study will also examine effects on vomiting, appetite, pain, fatigue, sleep, mood, quality of life, and inflammation. Results from this pilot study will help determine the safety, feasibility, and potential benefits of medical cannabis for chemotherapy-related nausea and guide future larger clinical trials.

Phase 2
Waitlist Available

University of Rochester Medical Center

Image of American University in Washington D.C., United States.

Dietary Intervention for Migraine

18 - 75
All Sexes
Washington D.C., United States

The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress. The main questions this study aims to answer are: Does following a low-glutamate diet reduce the number of migraine days and the severity and duration of migraine attacks, and improve quality of life? Are improvements in migraine symptoms associated with changes in blood-based biological markers related to migraine activity? Researchers will compare participants assigned to the low-glutamate diet with participants assigned to a wait-list control group to evaluate differences in migraine outcomes and related biological measures. Participants will: Complete a baseline run-in period while tracking headaches using a daily migraine diary Either follow a low-glutamate dietary intervention or continue their usual diet as part of a wait-list control Complete standardized questionnaires related to migraine symptoms and quality of life Provide blood samples for laboratory analyses Undergo neuroimaging assessments (for a subset of participants)

Waitlist Available
Has No Placebo

American University

Have you considered Metozolv Odt clinical trials?

We made a collection of clinical trials featuring Metozolv Odt, we think they might fit your search criteria.
Go to Trials
Image of Arizona State University in Phoenix, United States.

App-based Breathing Program for Migraine

18+
All Sexes
Phoenix, AZ

Migraine is one of the most common neurological disorders, characterized by recurrent headaches, sensitivity to light and movement, nausea, and autonomic dysregulation. Although mind-body interventions like biofeedback have shown their efficacy, they remain underutilized due to barriers such as transportation, time constraints, lack of awareness, stigma, and cost. A targeted approach to enhancing HRV is HRV biofeedback (HRVB), a technique using visual or auditory feedback to help people regulate HRV through slow-paced breathing and positive emotional regulation to promote ANS balance and emotional resilience. Investigators will conduct a remotely delivered pilot RCT of an 8-week, 10 min/day, novel app-based HRVB intervention compared to a sham control intervention (matching intervention time and attention with no biofeedback component) in adult with chronic migraine. Investigators hypothesize data collected from the study will: a) support the feasibility and acceptability of the remotely delivered app-based HRVB intervention among adults with chronic migraine, and b) provide insights into refining the intervention by examining patterns of change in migraine and psychological outcomes from pre- to post-intervention.

Waitlist Available
Online Trial

Arizona State University

Image of Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Canada.

Aprepitant for Postoperative Nausea and Vomiting

18+
All Sexes
Montreal, Canada

Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.

Phase 3
Waitlist Available

Centre hospitalier de l'Université de Montréal (CHUM)

Maxim Roy, MD, FRCPC

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD

This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.

Waitlist Available
Has No Placebo

Johns Hopkins Medicine

Risheng Xu, MD, PhD

Medtronic

Have you considered Metozolv Odt clinical trials?

We made a collection of clinical trials featuring Metozolv Odt, we think they might fit your search criteria.
Go to Trials
Image of Banner - University Medical Center South in Tucson, United States.

Dexmedetomidine + Dexamethasone for Postoperative Pain

18 - 75
All Sexes
Tucson, AZ

The goal of this clinical study is to improve upon the standard practice of utilizing nerve blocks to enhance the satisfaction of patients undergoing shoulder, or foot and ankle surgery regarding their quality of pain control, the duration of their nerve blocks, as well as the avoidance of opioid medications and subsequently their undesirable side effects. The researchers hypothesize that dexmedetomidine and dexamethasone (Dex-Dex) will work synergistically as adjuncts in a low, non-weight based formula. This would allow the investigators to improve patient satisfaction by providing them with a superior means of pain control that is longer in duration with a decreased probability of unwanted side effects. The proposed clinical study will be a prospective, randomized control trial.

Phase 1 & 2
Waitlist Available

Banner - University Medical Center South

Ronald Tang, MD

Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY

This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.

Phase 4
Recruiting

Mount Sinai Hospital

Jonathan Schimmel

Pfizer

Have you considered Metozolv Odt clinical trials?

We made a collection of clinical trials featuring Metozolv Odt, we think they might fit your search criteria.
Go to Trials